HEMOSIL RECOMBIPLASTIN 2G (8 ML VIAL)

{0} SPECIAL 510(k): Device Modification OIR Review Memorandum (Decision Making Document is Attached) To: THE FILE RE: DOCUMENT NUMBER: K132722 This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable: 1. The name and 510(k) number of the SUBMITTER'S previously cleared device (HemosIL RecombiPlasTin 2G, k070005). 2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use). 3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. This change was for modification to on-board stability claim for RecombiPlasTin 2G reagent (8mL vial) from 10 days at 15°C to 3 days at 15°C on the ACL Futura/ACL Advance. On-board stability also changed from 10 days at 15°C to 4 days at 15°C on the ACL ELITE and ACL TOP devices. 4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics, and on-board stability. (pp.61-62 of 178) 5. A Design Control Activities Summary which includes: a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis. The risk analysis was performed using a "RAW" (Risk Analysis Worksheet). The Risk Analysis Summary report is included on page 42 of 78, and fulfills the requirements of ISO 14971. b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied. Verification and validation activities and summary, p.50 of 78 and S001, p.17 of 175. c) A declaration of conformity with design controls. The declaration of conformity should include: i) A statement signed by the individual responsible, that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met. (pp.46-48) ii) A statement signed by the individual responsible, that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review. (pp.46-48) A Truthful and Accurate Statement (p.35 of 78), a 510(k) Statement (S001 p.11 of 175) and the Indications for Use Enclosure (S001 provided via email). The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.